Ser951

Site Information
kGtMDDIsQEEGssQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 460802
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ) , phospho-antibody ( 1 )
Disease tissue studied:	lung cancer ( 3 , 4 ) , non-small cell lung cancer ( 3 ) , non-small cell lung adenocarcinoma ( 3 , 4 ) , non-small cell large cell lung carcinoma ( 3 )
Relevant cell line - cell type - tissue:	HEK293T (epithelial) ( 1 , 10 ) , HeLa (cervical) ( 2 , 6 , 7 , 9 ) , Jurkat (T lymphocyte) ( 8 ) , K562 (erythroid) ( 5 ) , lung ( 3 , 4 ) , M059J (glial) ( 14 ) , M059K (glial) ( 11 , 12 , 13 ) , NCI-H1299 (pulmonary) ( 3 ) , NCI-H1734 (pulmonary) ( 3 ) , NCI-H1944 (pulmonary) ( 3 ) , NCI-H358 (pulmonary) ( 3 ) , NCI-H460 (pulmonary) ( 3 )

Upstream Regulation
Putative in vivo kinases:	ATM (human) ( 1 )
Treatments:	ionizing_radiation ( 1 , 10 ) , KU-60019 ( 1 ) , UV ( 10 )

References
1	Bass TE, Fleenor DE, Burrell PE, Kastan MB (2022) ATM Regulation of the Cohesin Complex is Required for Repression of DNA Replication and Transcription in the Vicinity of DNA Double Strand Breaks. Mol Cancer Res 36469004 Curated Info
2	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
3	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
4	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
5	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
6	Zhou J (2011) CST Curation Set: 11707; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S/TQG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S/TQG) Immunoaffinity Beads Cat#: 6969 Curated Info
7	Zhou J (2011) CST Curation Set: 11708; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S/TQG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S/TQG) Immunoaffinity Beads Cat#: 6969 Curated Info
8	Guo A (2011) CST Curation Set: 11731; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
9	Zhou J (2008) CST Curation Set: 4707; Year: 2008; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980 Curated Info
10	Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-6 17525332 Curated Info
11	Stokes M (2006) CST Curation Set: 1122; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
12	Stokes M (2006) CST Curation Set: 1124; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST] Curated Info
13	Stokes M (2006) CST Curation Set: 1093; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST] Curated Info
14	Stokes M (2005) CST Curation Set: 910; Year: 2005; Biosample/Treatment: cell line, M059J/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST] Curated Info